MaxCyte, Inc. $MXCT Shares Acquired by Renaissance Technologies LLC

Renaissance Technologies LLC increased its stake in shares of MaxCyte, Inc. (NASDAQ:MXCT) by 153.3% in the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 1,993,200 shares of the company’s stock after purchasing an additional 1,206,300 shares during the quarter. Renaissance Technologies LLC owned 1.86% of MaxCyte worth $1,400,000 at the end of the most recent quarter.

A number of other hedge funds also recently bought and sold shares of the stock. Capricorn Fund Managers Ltd acquired a new position in shares of MaxCyte during the first quarter worth $5,760,000. Brooklands Fund Management Ltd acquired a new stake in MaxCyte in the first quarter valued at $1,538,000. Kennedy Capital Management LLC purchased a new stake in MaxCyte during the 3rd quarter worth about $3,330,000. AXA S.A. boosted its position in shares of MaxCyte by 123.2% during the 2nd quarter. AXA S.A. now owns 2,202,378 shares of the company’s stock worth $4,801,000 after acquiring an additional 1,215,481 shares in the last quarter. Finally, Millennium Management LLC increased its holdings in shares of MaxCyte by 1,082.6% in the 4th quarter. Millennium Management LLC now owns 1,292,773 shares of the company’s stock valued at $2,004,000 after acquiring an additional 1,183,461 shares during the last quarter. Institutional investors and hedge funds own 68.81% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities research analysts recently weighed in on the company. Wall Street Zen upgraded MaxCyte from a “sell” rating to a “hold” rating in a research note on Saturday, May 16th. Weiss Ratings raised shares of MaxCyte from a “sell (e+)” rating to a “sell (d-)” rating in a report on Tuesday, July 28th. One equities research analyst has rated the stock with a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and a consensus target price of $5.00.

MaxCyte Stock Performance

Shares of MXCT stock opened at $1.27 on Thursday. The stock’s 50-day moving average is $1.19 and its two-hundred day moving average is $0.98. MaxCyte, Inc. has a 1 year low of $0.64 and a 1 year high of $1.86. The firm has a market cap of $136.04 million, a price-to-earnings ratio of -3.43 and a beta of 1.48.

MaxCyte (NASDAQ:MXCT) last posted its earnings results on Wednesday, August 12th. The company reported ($0.08) earnings per share for the quarter, beating the consensus estimate of ($0.09) by $0.01. The business had revenue of $6.50 million during the quarter, compared to the consensus estimate of $6.51 million. MaxCyte had a negative return on equity of 20.03% and a negative net margin of 121.16%. As a group, research analysts predict that MaxCyte, Inc. will post -0.29 EPS for the current year.

MaxCyte Profile

MaxCyte, Inc (NASDAQ: MXCT) is a clinical‐stage cell therapy platform company that develops and commercializes proprietary flow electroporation technology for the delivery of macromolecules into living cells. The company’s instruments and consumables are designed to support research, preclinical development and clinical‐scale manufacturing of cell therapies across a variety of modalities, including engineered T cells, natural killer (NK) cells and induced pluripotent stem cell (iPSC) therapies.